Jaana Grüter of Keensight Capital Joins the CatSci Board of Directors
CatSci Ltd is thrilled to announce that, as part of our investment deal with Keensight Capital, Jaana Grüter has joined the Board of Directors of CatSci’s parent company. Jaana is a Managing Director at Keensight, and we are incredibly fortunate that she will be bringing her deep experience in healthcare investments to CatSci.
Keensight Capital is one of the leading private equity managers dedicated to pan-European Growth Buyout Investments, and recently invested into CatSci to support our ambitious expansion plans. This will allow us to significantly grow our capabilities, workforce, laboratories, facilities, and offerings, enabling us to offer even more and better to our customers as we move towards becoming a fully integrated partner of choice for pharmaceutical companies all over the globe. Jaana has specialised in healthcare Investments since 2015, when she joined Keensight Capital as an Associate Director, so she is the perfect addition to join us on this mission.
Janna will be bringing with her a wealth of experience in corporate financing and business development, as well as a fresh perspective and new ideas. She graduated from Maastricht University in 2008 with an MSc in International Business with a specialisation in Finance. She then began her career at Rothschild & Co in Paris, where she gained five years’ experience in general Mergers & Acquisitions Advisory. She moved on and became an Investment Associate at Five Arrows Principal Investments, before beginning her role at Keensight.
Jaana has held the role of Managing Director at Keensight Capital since November 2021 and joined the Board of Directors of CatSci’s parent company in June 2022. As an Investor Director, she will be influential in accelerating the business development strategy with her years of experience in helping businesses unlock their full potential through investment. As the company grows from strength to strength, our expansion plans will allow us to offer more and better services to enhance the ever-evolving medicines development partnerships with our customers that deliver much needed new therapeutics to patients in need.
Jaana said: “I am thrilled to be joining the CatSci team. They are at a very exciting stage of their journey, and myself and Keensight are very happy to be working together with them. Everyone in CatSci has shown a great energy and commitment to accelerating medicines development, and we are delighted to be joining them on this mission. We look forward to a long, prosperous relationship together, and continuing to further grow and develop this amazing company.”